Evidence map›Paper›PMID 42006279›Full record

ArticleJTO clinical and research reports2026

Impacts of Multidisciplinary Lung Cancer Meeting Presentation in a Clinical Quality Registry.

Rob G Stirling, Sanuki Tissera, Jessie Zeng, Mike Lloyd, Krupa Krishnaprasad, Lisa Briggs, Jacqueline Lesage, Tom Wood, Craig Underhill, Sagun Parakh and 24 more

Abstract read
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Rob G StirlingSchool of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Sanuki TisseraSchool of Public Health and Preventive Medicine, Monash University, Victoria, Australia.
Jessie ZengSchool of Public Health and Preventive Medicine, Monash University, Victoria, Australia.
Mike LloydSchool of Public Health and Preventive Medicine, Monash University, Victoria, Australia.
Krupa KrishnaprasadSchool of Public Health and Preventive Medicine, Monash University, Victoria, Australia.
Lisa BriggsLung Cancer Advocate, Melbourne, Victoria, Australia.
Jacqueline LesageLung Cancer Advocate, Melbourne, Victoria, Australia.
Tom WoodLung Cancer Advocate, Melbourne, Victoria, Australia.
Craig UnderhillUniversity of New South Wales (NSW) Rural Medical School Albury, New South Wales, Australia.
Sagun ParakhOlivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia.
Louis IrvingDepartment of Respiratory and Sleep Medicine, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Wasek FaisalDepartment of Medical Oncology, Grampians Health, Ballarat, Victoria, Australia.
Robert BlumBendigo Health Oncology Unit, Bendigo Health, Victoria, Australia.
Gary RichardsonDepartment of Medical Oncology, Cabrini Health, Malvern, Victoria, Australia.
Phillip ParenteMedical Oncology, Eastern Health, Box Hill, Victoria, Australia.
Michelle CaldecottDepartment of Medicine, Epworth Healthcare, Richmond, Victoria, Australia.
Inger OlesenAndrew Love Cancer Centre, Barwon Health, Geelong, Victoria, Australia.
Javier TorresMedical Oncology, Goulbourn Valley Health, Shepparton, Victoria, Australia.
Evangeline SamuelDepartment of Medical Oncology, Latrobe Regional Health, Victoria, Australia.
Christopher LyneDepartment of Respiratory Medicine, Monash Medical Centre, Clayton, Victoria, Australia.
Katharine SeeDepartment of Respiratory Medicine, Northern Health, Epping, Victoria, Australia.
David LangtonDepartment of Respiratory Medicine, Peninsula Health, Frankston, Victoria, Australia.
Tom JohnDepartment of Medical Oncology, Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia.
Gavin M WrightDepartment of Cardiothoracic Surgery, University of Melbourne, Melbourne, Victoria, Australia.
Matthew ConronDepartment of Respiratory Medicine, St Vincent's Hospital, Melbourne, Victoria, Australia.
James BartlettDepartment of Respiratory Medicine, Western Health, Footscray, Victoria, Australia.
Nicola AtkinParkville Integrated Palliative Care Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Maggie MooreSchool of Public Health and Preventive Medicine, Monash University, Victoria, Australia.
Golsa AdabiDepartment of Respiratory Medicine, Alfred Health, Melbourne, Victoria, Australia.
Luke CleggDepartment of Respiratory Medicine, Alfred Health, Melbourne, Victoria, Australia.
Nikolajs ZepsSchool of Public Health and Preventive Medicine, Monash University, Victoria, Australia.
Susan HardenSchool of Public Health and Preventive Medicine, Monash University, Victoria, Australia.
Zoe McQuiltenSchool of Public Health and Preventive Medicine, Monash University, Victoria, Australia.
John ZalcbergSchool of Public Health and Preventive Medicine, Monash University, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung cancer is a heterogeneous and complex disease requiring multidisciplinary input for optimal management planning, with guidelines recommending that all patients be discussed in a multidisciplinary setting. Multidisciplinary meeting (MDM) discussion aims to enhance evidence-based management, improve treatment access, and optimize complex management plans. Methods: We aimed to assess the extent and impacts of MDM discussion in patients with lung cancer described by the Victorian Lung Cancer Registry from 2011 to 2023 in Victoria, Australia. We identified MDM-presented and nonpresented patients and assessed the impacts of MDM presentation. OR and survival hazard ratios were assessed using Cox proportional regression analysis. Survival analysis was determined using the Kaplan-Meier product-limit method. Sensitivity analyses were conducted using landmark analysis and propensity score matching methods. Results: A total of 18,597 patients were included, of whom 67% had evidence of presentation to a lung cancer MDM, with MDM presentation increasing from 59.1% to 80.6% during the study period. MDM presentation was associated with higher levels of provision of guideline-concordant treatment in NSCLC (56.2% versus 44.5%, Conclusion: During the period of activity of the Victorian Lung Cancer Registry, MDM presentation increased from 59.1% to 80.6%. Management outcomes in MDM-presented patients identified multiple underserved cohorts and revealed considerable increases in treatment modalities and guideline-concordant treatment in NSCLC in this observational study, with an associated 12% improvement in survival advantage overall.

Indexed as

Benchmark reportingClinical quality registryLung cancerMultidisciplinary MeetingQuality Improvement

Identifiers

PMID42006279
PMCPMC13089129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.